Palatin Technologies, Inc. (PTNT)
OTCMKTS · Delayed Price · Currency is USD
5.95
+0.20 (3.46%)
At close: Oct 28, 2025

Palatin Technologies Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.

It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.

The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.

Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Palatin Technologies, Inc.
CountryUnited States
Founded1986
IndustryBiotechnology
SectorHealthcare
Employees29
CEOCarl Spana

Contact Details

Address:
11 Deer Park Drive
Monmouth Junction, Delaware 08512
United States
Phone609 495 2200
Websitepalatin.com

Stock Details

Ticker SymbolPTNT
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJuly - June
Reporting CurrencyUSD
SIC Code2836

Key Executives

NamePosition
Dr. Carl Spana Ph.D.Co-Founder, President, Chief Executive Officer and Director
Stephen T. Wills CPA, MSTChief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary
Burns McClellanVice President of Investor Relations
Stephen A. Slusher Esq.Chief Legal Officer
Dr. Michael B. Raizman M.D.Chief Medical Officer
James E. Hattersley B.A., M.S.Senior Vice President of Business Development
John Dodd Ph.D.Senior Vice President of Preclinical Development
Robert JordanSenior Vice President of Program Operations